Clorox Reports 33% First-Quarter Sales Growth as Margins Slip
Clorox reported $1.91B in Q1 sales, up 33% YoY, driven by its GOJO acquisition. Organic sales rose 18%, while gross margin fell to 40.4% due to higher costs. EPS increased 114% to $1.39. CEO Linda Rendle noted results exceeded expectations but highlighted higher inflationary pressures.
How this was made
The 30-second read
Why it matters
Earnings beat and strong sales growth provide a catalyst for short‑term upside, though margin pressure tempers the rally.
Market read
The earnings surprise is likely to move CLX and influence the consumer staples sector.
What to watch
The integration of GOJO may introduce integration risk and future cost pressures.
Background
Clorox's Q1 results reflect a rebound after inventory drawdown and the contribution of its recent GOJO acquisition.
Ticker impact
Clorox reported Q1 sales of $1.91B, up 33% YoY, and diluted EPS of $1.39, up 114% YoY.
upward pressure as the market prices in the earnings beat and higher sales momentum.
The magnitude of sales growth and EPS surge for a large‑cap consumer staple is material and fresh, prompting traders to consider buying on the upside.
Market effects
Positive earnings may boost the broader household products sector and peers such as Procter & Gamble.
U.S. consumer‑staples index could see modest gains.
Limited to U.S. markets; no direct global macro effect.
Counterpoint
Margin compression and higher commodity costs could weigh on profitability if growth slows.
Key entities
- companyClorox Company
U.S. consumer‑staples firm reporting Q1 2027 results.
- companyGOJO
Acquired firm contributing to sales growth.
